Monthly Archives: July 2014

DSMB recommendation and HCV trial update of Benitec.

Sydney Australia, 21 July 2014: RNAi therapeutics company Benitec Biopharma
Limited (ASX: BLT, OTC: BTEBY) is pleased to provide an update regarding
recommendations from the Data Safety Monitoring Review Board (DSMB),
observations from the first patient dosed, and patient recruitment for the USJbased
Phase I/IIa TTJ034 clinical trial. TTJ034 is a ddRNAiJbased therapeutic, designed to
treat and potentially cure hepatitis C (HCV) with a single injection.
DSMB recommendation and observations from first patient dosed
Following review of data from the first patient treated with TTJ034 on 29 May 2014,
the … Read more

mRNA-based vaccines

TUBINGEN, Germany, July 1, 2014 /PRNewswire/ — CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi , to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

In 2011, CureVac and Sanofi Pasteur signed a collaboration and license option agreement for several pre-defined pathogens. CureVac met all pre-agreed milestones and acceptance criteria relating to these agreements, and therefore Sanofi Pasteur exercised its first option and extended its exclusive and non-exclusive options on all five … Read more